Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, Mizuho Analyst Says

Enliven Therapeutics (NASDAQ:ELVN) had its target price upped by research analysts at Mizuho from $41.00 to $45.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price suggests a potential upside of 14.53% from the stock’s current price.

Several other research analysts also recently weighed in on ELVN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $39.29 on Wednesday. The company has a 50-day simple moving average of $28.32 and a 200-day simple moving average of $22.84. The company has a market cap of $2.35 billion, a PE ratio of -21.12 and a beta of 0.33. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $40.62.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current year.

Insider Activity at Enliven Therapeutics

In related news, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares in the company, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph P. Lyssikatos sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $29.04, for a total transaction of $145,200.00. Following the transaction, the insider directly owned 740,188 shares of the company’s stock, valued at $21,495,059.52. This trade represents a 0.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 232,180 shares of company stock valued at $6,217,033 over the last three months. Insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares during the period. Invesco Ltd. grew its position in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after acquiring an additional 913 shares during the period. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Swiss National Bank raised its holdings in shares of Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares during the period. Finally, Quantbot Technologies LP raised its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Enliven Therapeutics

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 and maintained a Buy rating, implying sizable upside versus recent levels — a clear catalyst for investor demand. HC Wainwright raises PT to $56 (Benzinga)
• Positive Sentiment: Mizuho boosted its target to $45 and set an Outperform rating, reinforcing the analyst upgrade momentum and providing additional institutional validation. Mizuho raises PT to $45 (Benzinga)
• Positive Sentiment: Merck’s $6.7B acquisition of Terns lifted sentiment across the oncology group and directly benefited Enliven by highlighting the value of blood-cancer programs, which helped spark a large intraday jump in ELVN shares. Merck buys Terns — ELVN share reaction (MSN)
• Positive Sentiment: Coverage notes that ELVN has hit new multi‑year and 52‑week highs as analysts turn upbeat, which can attract momentum and crossover buying from funds tracking breakouts. ELVN hits 52-week high (American Banking News)
• Neutral Sentiment: Several media outlets and aggregator posts are amplifying the price-target changes and deal-driven optimism; this increases visibility but doesn’t change fundamentals immediately. Coverage roundup (Kalkine Media)

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.